HOME >> MEDICINE >> NEWS
Tiny newborns face higher risk of death at community hospitals, Stanford/VA study finds

STANFORD, Calif. - More than 20 percent of very small babies who died in California between 1991 and 2000 might have lived had they been born in different hospitals, say researchers at the Stanford University School of Medicine and the Veterans Affairs Palo Alto Health Care System.

Consolidating the risky deliveries at highly experienced regional medical centers may be one way to give the very-low-birth-weight newborns, who weigh less than 3.3 pounds, their best chance of survival, they concluded.

Although the findings show that such a proposal is feasible, it flies in the face of a growing trend of decentralization in which community hospitals with lower-level neonatal intensive care units are shouldering an increasing number of complex patients.

"We can do better," said Ciaran Phibbs, PhD, a health economist at the Health Economics Resource Center at the Veterans Affairs Palo Alto Health Care System and an associate professor of pediatrics at Stanford's School of Medicine. "Although being born in a place with a mid-level neonatal intensive care unit is better than a place with no neonatal ICU at all, we found that these extremely tiny newborns were significantly more likely to survive in hospitals that cared for at least 100 such infants each year."

Phibbs is the lead author of the study, which will be published in the May 24 issue of the New England Journal of Medicine.

The risks are real. Although very-low-birth-weight infants account for between 1 and 2 percent of births each year in California, they make up 51 percent of infant deaths.

Neonatal ICUs are classified according to the kind of care they can provide. The neonatal ICU at Lucile Packard Children's Hospital at Stanford is a level-3D center - the highest level reserved for hospitals that perform on-site cardiac surgery and a type of heart/lung bypass for newborns. Packar
'"/>

Contact: Krista Conger
kristac@stanford.edu
650-725-5371
Stanford University Medical Center
23-May-2007


Page: 1 2 3

Related medicine news :

1. Vaginal birth increases risk of hemorrhage in newborns
2. Imaging technique is highly accurate in diagnosing, locating pancreas defects in newborns
3. Violence from male partners associated with serious health threats to pregnant women and newborns
4. High rates of caesarean delivery may harm mothers and newborns
5. Study shows newborns with jaundice at no greater risk
6. Antidepressant use during pregnancy appears associated with withdrawal symptoms in newborns
7. Cool therapy reduces brain injury and death from oxygen loss in newborns
8. Opiates better than sedatives for treating newborns in withdrawal
9. Asymptomatic HIV-infected newborns may benefit from early drug treatment, Stanford study shows
10. Women with migraines and visual symptoms may have higher stroke risk
11. Study explains why patients with OSA are at higher risk for cardiovascular disease

Post Your Comments:
(Date:1/22/2015)... IsoComforter, Inc. has introduced the most innovative and ... to treat specific body parts and muscle groups. , ... to use patented cold therapy machine with the innovative IsoTube ... muscle injuries. IsoComforter has become the industry leader in ...
(Date:1/22/2015)... January 22, 2015 Payday lending practices ... communities and cause financial distress to the states that ... at Howard University’s Center on Race and Wealth. , ... economic activity, payday loans at the same time substantially ...
(Date:1/22/2015)... 2015 As interest in the value of ... momentum worldwide, Rev. Eric J. Hall , president and ... (HCCN), will be the keynote speaker on January 27 at ... health system. , The conference, “Hope and Resilience: Innovative and ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 Compare-autoinsurance.org has released a ... insured by an auto insurance policy . , Some ... policy. Clients should check the newly released blog post to see ... cars and dangerously damaged vehicles are some of the cars that ...
(Date:1/22/2015)... VA (PRWEB) January 22, 2015 Step ... power at the Science Museum of Virginia. Wicked Plants, ... , Wicked Plants unearths 75 poisonous, carnivorous and diabolical ... through each room to uncover the biochemical, physical and ...
Breaking Medicine News(10 mins):Health News:IsoComforter Introduces Best of Class Cold Therapy Product to the Worldwide Market 2Health News:Howard University Spotlights the Economic Impact of Payday Lending in Southern States 2Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 2Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 3Health News:Some Vehicles Cannot Be Covered By An Auto Insurance Policy! 2Health News:Wicked Plants are taking over the Science Museum of Virginia 2
(Date:1/23/2015)... and DUBLIN , Jan. 23, 2015  Immune ... KRS Global Biotechnology, Inc. for the compounding, packaging and distributing ... shipment in the United States . ... Facility capable of compounding naltrexone tablets in various strengths for ...
(Date:1/23/2015)...  HyGreen, Inc., a leader in hand hygiene monitoring, today ... a subsidiary of Ascendis Health Limited, in ... hundreds of millions of patients around the world are ... from patient to patient via the unwashed hands of ...
(Date:1/23/2015)...  Lixte Biotechnology Holdings, Inc. (OTCQB: LIXT), announced that the number ... lead compound, LB‑100, is being conducted, has been expanded from ... , M.D., the founder and President of Lixte, said that, ... single site. Accrual of patients, however, was slower than projected. ...
Breaking Medicine Technology:Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. 2Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. 3Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. 4HyGreen Partners with RCA Medical in Johannesburg, South Africa 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 3
Cached News: